BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.
Colorectal Cancer
DRUG: Brivanib + Cetuximab
Safety assessment, throughout the study|dose limiting toxicity (DLT), assessed for individual patients from C1D1 to C1D28 during the dose escalation portion of the protocol, until maximum tolerated dose is identified|determination of maximum tolerated dose (MTD), during dose escalation portion of the protocol. Three to six subjects are treated at a specified dose level. If deemed safe dose escalation continues until the maximu tolerated dose is identified
Efficacy based on duration of response and time to progression based on assessment, Measured every 8 weeks throughout the study
This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.